An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy
Stopped Termination Date: 30Aug2018; Reason for termination: Lack of Efficacy
Conditions
- Duchenne Muscular Dystrophy
Interventions
Sponsor
Pfizer